Psoriasis

Join Clinical Trials for Psoriasis

Join Clinical Trials for Psoriasis

General purpose: 

Research related to psoriasis may study genetic factors associated with the development of psoriasis, the role of the immune system in the development of psoriasis.

How various treatments for psoriasis affect the skin and joints, and how psoriasis increases the risk of other health problems, like diabetes, cancer, and heart disease.

Research may also look at new methods of treating psoriasis and any side effects that they cause.

About Psoriasis Clinical Trials (Click to Open)

Join Clinical Trials for Psoriasis

Psoriasis Clinical Trials

What do clinical trials for Psoriasis involve?

Clinical trials will vary widely in the information they collect, as well as the tests and procedures they use.

All of these factors will depend on individual study designs, which will differ greatly between trials. However, below is a list of common procedures and data that are frequently collected during a trial for psoriasis:

  • Subjective reporting by the patient as to the severity and tolerability of their psoriasis symptoms.
  • Visual inspection and evaluation of psoriasis skin lesions to determine their redness, thickness, and scaliness.
  • Skin biopsy
  • Photographs of psoriasis lesions.
  • Assessments of how psoriasis is affecting the patient’s quality of life.

Examples of Psoriasis- related research topics:

  • Studies comparing a conventional treatment for psoriasis with a newly developed drug to determine which is most effective.
  • Studies that investigate new treatments that are designed to help the skin resist to attacks from the immune system.
  • Studies designed to evaluate the use and effectiveness of laser treatment for psoriasis lesions.
  • Studies investigating the interaction between specific genes and environmental factors, and how that interaction increases the risk of developing psoriasis.
  • Studies that evaluate the effectiveness of treatments that target specific immune system cells that attack the skin and promote the inflammation see in psoriasis.

Suggested search terms for Psoriasis:  

“Psoriasis” “psoriasis treatment,” “psoriasis laser therapy,” “psoriasis arthritis,” “psoriasis cardiovascular,” “psoriasis symptoms,” and “psoriasis vitamins.”



Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies


Condition:   Psoriasis
Intervention:   Drug: Brodalumab
Sponsor:   Icahn School of Medicine at Mount Sinai
Recruiting


Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis


Condition:   Psoriasis
Interventions:   Drug: ARQ-151 cream 0.5%;   Drug: ARQ-151 cream 0.15%;   Drug: ARQ-151 cream placebo
Sponsor:   Arcutis, Inc.
Recruiting


Safety and Efficacy of Secukinumab in Mild Psoriasis


Condition:   Psoriasis
Interventions:   Drug: Secukinumab;   Drug: Placebo followed by Secukinumab
Sponsors:   James G. Krueger, MD, PhD;   Novartis
Recruiting


Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab


Condition:   Psoriasis
Intervention:  
Sponsor:   AbbVie
Recruiting


Efficacy and Tolerability of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis


Conditions:   Psoriasis;   Psoriasis Vulgaris
Interventions:   Drug: HAT1 topical solution;   Drug: Calcipotriol
Sponsor:   Haus Bioceuticals
Completed


Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis


Condition:   Plaque Psoriasis
Interventions:   Drug: Secukinumab 150 mg s.c.;   Drug: Secukinumab 300 mg s.c.;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Active, not recruiting


Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis


Condition:   Plaque Psoriasis
Interventions:   Biological: Secukinumab;   Radiation: nbUVB;   Drug: Calcipotriol;   Drug: Betamethasone
Sponsor:   Novartis Pharmaceuticals
Recruiting


A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis


Condition:   Psoriasis
Interventions:   Drug: GSK2981278 ointment;   Drug: Vehicle ointment
Sponsor:   GlaxoSmithKline
Completed


Efficacy and Safety Study of NP000888 in Subjects With Plaque and Nail Psoriasis


Condition:   Psoriasis
Interventions:   Drug: NP000888;   Drug: Vehicle
Sponsor:   Galderma R&D
Active, not recruiting


Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis


Condition:   Chronic Plaque Psoriasis
Interventions:   Drug: PF-06700841;   Other: Placebo
Sponsor:   Pfizer
Active, not recruiting


BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test


Condition:   Psoriasis
Interventions:   Drug: BAY1003803;   Drug: Clobetasol propionate;   Drug: Betamethasone/calcipotriene
Sponsor:   Bayer
Completed


LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris


Condition:   Psoriasis Vulgaris
Interventions:   Drug: LEO 32731;   Drug: LEO 32731 Placebo
Sponsor:   LEO Pharma
Completed



Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp Psoriasis


Condition:   Scalp Psoriasis
Interventions:   Drug: 0.25% Desoximetasone cream (Topoxy®);   Drug: 0.25% Desoximetasone cream (Topicorte®);   Drug: Placebo
Sponsors:   Siriraj Hospital;   SPS MEDICAL CO.,LTD.;   Siriraj clinical research center
Recruiting


The Corrona Psoriasis (PSO) Registry


Condition:   Psoriasis
Intervention:  
Sponsor:   Corrona, LLC.
Enrolling by invitation


The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis


Condition:   Psoriasis
Interventions:   Drug: Riboflavin;   Other: Placebo
Sponsor:   University of Michigan
Recruiting


Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Nails Affected by Psoriasis


Condition:   Nail Psoriasis
Interventions:   Drug: P-3073;   Drug: Vehicle of P-3073
Sponsor:   Polichem S.A.
Completed


Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis


Conditions:   Chronic Plaque Psoriasis;   Psoriasis
Interventions:   Biological: M923;   Biological: Humira
Sponsor:   Momenta Pharmaceuticals, Inc.
Completed


Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients


Condition:   Psoriasis
Intervention:  
Sponsors:   University of Rochester;   Rheumatology Research Foundation
Active, not recruiting


Plaque Psoriasis Efficacy and Safety With Secukinumab


Condition:   Plaque Psoriasis
Intervention:   Biological: Secukinumab
Sponsor:   Novartis Pharmaceuticals
Completed


Excimer Laser, Serum Markers & Psoriasis


Condition:   Psoriasis
Intervention:   Device: Excimer laser treatment
Sponsors:   University Hospitals Cleveland Medical Center;   Photomedex
Completed


Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis


Condition:   Psoriasis
Intervention:  
Sponsors:   Northwestern University;   AbbVie
Recruiting


Clinical Trial of PSORI-CM01(YXBCM01) Granule to Treat Stable Plaque Psoriasis


Condition:   Plaque Psoriasis
Interventions:   Drug: PSORI-CM01(YXBCM01) granule;   Drug: placebo
Sponsor:   Guangdong Provincial Hospital of Traditional Chinese Medicine
Terminated


Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis


Condition:   Psoriasis
Intervention:  
Sponsors:   Assistance Publique - Hôpitaux de Paris;   French Health Products Safety Agency;   Société de Dermatologie Française;   Janssen, LP;   Pfizer;   AbbVie;   Merck Sharp & Dohme Corp.
Recruiting


AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis


Condition:   Psoriasis
Interventions:   Drug: AN2728 ointment, 2%;   Drug: Ointment Vehicle
Sponsor:   Pfizer
Completed

Refine Your Search Advanced Search